ES2607125T3 - Compuestos de tetrazolo[1,5-a]pirazina como inhibidores de receptores de histamina - Google Patents

Compuestos de tetrazolo[1,5-a]pirazina como inhibidores de receptores de histamina Download PDF

Info

Publication number
ES2607125T3
ES2607125T3 ES11754043.5T ES11754043T ES2607125T3 ES 2607125 T3 ES2607125 T3 ES 2607125T3 ES 11754043 T ES11754043 T ES 11754043T ES 2607125 T3 ES2607125 T3 ES 2607125T3
Authority
ES
Spain
Prior art keywords
mmol
chosen
piperazin
tert
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11754043.5T
Other languages
English (en)
Spanish (es)
Inventor
Allen Borchardt
Robert Davis
Stewart A. Noble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kalypsys Inc
Original Assignee
Kalypsys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys Inc filed Critical Kalypsys Inc
Application granted granted Critical
Publication of ES2607125T3 publication Critical patent/ES2607125T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES11754043.5T 2010-03-10 2011-03-10 Compuestos de tetrazolo[1,5-a]pirazina como inhibidores de receptores de histamina Active ES2607125T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31261510P 2010-03-10 2010-03-10
US312615P 2010-03-10
PCT/US2011/027817 WO2011112766A2 (en) 2010-03-10 2011-03-10 Heterocyclic inhibitors of histamine receptors for the treatment of disease

Publications (1)

Publication Number Publication Date
ES2607125T3 true ES2607125T3 (es) 2017-03-29

Family

ID=44564108

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11754043.5T Active ES2607125T3 (es) 2010-03-10 2011-03-10 Compuestos de tetrazolo[1,5-a]pirazina como inhibidores de receptores de histamina

Country Status (18)

Country Link
US (1) US8569300B2 (https=)
EP (1) EP2545058B1 (https=)
JP (1) JP5888654B2 (https=)
KR (1) KR20130016253A (https=)
CN (1) CN102869666B (https=)
AR (1) AR080496A1 (https=)
AU (1) AU2011224316B2 (https=)
BR (1) BR112012022211A2 (https=)
CA (1) CA2791417A1 (https=)
ES (1) ES2607125T3 (https=)
IL (1) IL221829A (https=)
MX (1) MX2012010404A (https=)
NZ (1) NZ602041A (https=)
PH (1) PH12012501783A1 (https=)
RU (1) RU2012137180A (https=)
TW (1) TW201200518A (https=)
UY (1) UY33271A (https=)
WO (1) WO2011112766A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859550B2 (en) * 2011-09-12 2014-10-14 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
AU2014261070A1 (en) 2013-05-02 2015-10-29 Pfizer Inc. Imidazo-triazine derivatives as PDE10 inhibitors
EP3290407B1 (en) 2013-10-18 2020-01-01 Celgene Quanticel Research, Inc Bromodomain inhibitors
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
MX373103B (es) 2014-02-13 2020-04-17 Incyte Holdings Corp Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
CA2969090C (en) 2014-12-23 2023-05-02 Novartis Ag Triazolopyrimidine compounds and uses thereof
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
JP6999574B2 (ja) 2016-04-22 2022-01-18 インサイト・コーポレイション Ｌｓｄ１阻害剤の製剤
WO2017221100A1 (en) 2016-06-20 2017-12-28 Novartis Ag Imidazopyrimidine compounds useful for the treatment of cancer
JP7042812B2 (ja) 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
MX2019008229A (es) 2017-01-10 2019-10-24 Bayer Ag Derivados heterociclicos como agentes de control de plagas.
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
MY200629A (en) 2017-08-01 2024-01-06 Theravance Biopharma R&D Ip Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
MX2020003579A (es) * 2017-10-12 2020-07-22 Revolution Medicines Inc Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
BR112020009757A2 (pt) * 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
KR102614939B1 (ko) * 2018-02-13 2023-12-19 블루레이 테라퓨틱스 (상하이) 컴퍼니 리미티드 피리미딘-융합고리 화합물 및 그의 제조방법과 용도
CN110655520A (zh) * 2018-06-29 2020-01-07 上海青煜医药科技有限公司 嘧啶并环化合物及其制备方法和应用
CN110156786B (zh) * 2018-02-13 2022-06-03 青煜医药研发(上海)有限公司 嘧啶并环化合物及其制备方法和应用
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
ES2973117T3 (es) 2018-09-25 2024-06-18 Incyte Corp Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
JP2022506887A (ja) * 2018-11-07 2022-01-17 シャンハイ リンジーン バイオファーマ カンパニー リミテッド 窒素含有縮合複素環系ｓｈｐ２阻害剤化合物、製造方法及び使用
CN113272303B (zh) * 2018-11-30 2024-09-17 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
PH12022550441A1 (en) * 2019-08-22 2022-12-19 Blueray Therapeutics Shanghai Co Ltd Azaheteroaryl compound and application thereof
US12065444B2 (en) * 2021-11-19 2024-08-20 Crossignal Therapeutics, Inc. Substituted tetrazolo[1,5-a]pyrazines and tetrazolo[1,5-c]pyrimidines as adenosine receptor antagonists

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929812A (en) * 1974-05-20 1975-12-30 Squibb & Sons Inc Derivatives of 1H-triazolo {8 4,5-c{9 pyridine-7-carboxylic acids and esters
DE4337611A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
JPWO2003028732A1 (ja) * 2001-09-28 2005-01-13 協和醗酵工業株式会社 受容体拮抗剤
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
CN1310916C (zh) * 2002-06-25 2007-04-18 协和发酵工业株式会社 双环类杂环化合物
WO2004022060A2 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
CA2569887A1 (en) * 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
WO2007063934A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
PT2029602E (pt) * 2006-05-31 2010-07-08 Galapagos Nv Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
US20100016293A1 (en) * 2006-07-03 2010-01-21 Rogier Adriaan Smits Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
WO2008031556A2 (en) 2006-09-12 2008-03-20 Ucb Pharma, S.A. 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
PL2247294T3 (pl) * 2008-02-08 2014-09-30 Basilea Pharmaceutica Ag Makrolidy do leczenia chorób przez hamowanie PDE
TW201024297A (en) 2008-09-10 2010-07-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
AU2009291783A1 (en) * 2008-09-10 2010-03-18 Alcon Research, Ltd Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
SG175195A1 (en) * 2009-04-16 2011-11-28 Ct Nac Investigaciones Oncologicas Cnio Imidazopyrazines for use as kinase inhibitors
EP2464647B1 (en) * 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
RS54772B1 (sr) 2009-12-17 2016-10-31 Merial Sas Antiparazitska jedinjenja dihidroazola i kompozicije koje ih sadrže
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
US20110237599A1 (en) * 2010-03-10 2011-09-29 Kalypsys, Inc. Heterocyclic inhibitors of histamine receptors for the treatment of disease

Also Published As

Publication number Publication date
MX2012010404A (es) 2013-05-20
JP5888654B2 (ja) 2016-03-22
BR112012022211A2 (pt) 2017-07-18
TW201200518A (en) 2012-01-01
EP2545058B1 (en) 2016-08-24
WO2011112766A3 (en) 2012-01-19
KR20130016253A (ko) 2013-02-14
JP2013522222A (ja) 2013-06-13
CN102869666A (zh) 2013-01-09
NZ602041A (en) 2014-08-29
US20110237565A1 (en) 2011-09-29
PH12012501783A1 (en) 2015-06-26
WO2011112766A2 (en) 2011-09-15
US8569300B2 (en) 2013-10-29
UY33271A (es) 2011-10-31
AU2011224316A1 (en) 2012-09-13
CA2791417A1 (en) 2011-09-15
AR080496A1 (es) 2012-04-11
AU2011224316B2 (en) 2016-09-15
CN102869666B (zh) 2015-09-09
IL221829A (en) 2014-11-30
EP2545058A4 (en) 2013-07-24
RU2012137180A (ru) 2014-04-20
EP2545058A2 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
ES2607125T3 (es) Compuestos de tetrazolo[1,5-a]pirazina como inhibidores de receptores de histamina
KR101970837B1 (ko) 항바이러스제로서의 피라졸로[1,5-ａ]피리미딘
AU2013334236B2 (en) Heteroaryl inhibitors of PDE4
AU2014400628B2 (en) Aminopyridazinone compounds as protein kinase inhibitors
US20100120741A1 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
ES2927021T3 (es) Compuestos heteroaromáticos como inhibidores de vanina
US20110257137A1 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN102186479A (zh) 用于治疗疾病的组胺受体的氨基嘧啶抑制剂
US20110237599A1 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN111433200A (zh) 用于治疗疾病的新化合物及其药物组合物
US8080566B1 (en) Carbazole inhibitors of histamine receptors for the treatment of disease
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
JP2022531088A (ja) Ｊａｋ阻害剤としての置換ピロロピリジン
JP2013533868A (ja) タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用
CN117396473A (zh) 血浆激肽释放酶的咪唑并吡啶基抑制剂
JP6703989B2 (ja) 呼吸器合胞体ウイルス（ｒｓｖ）の複製への阻害活性を有するピペリジン置換三環式ピラゾロ［１，５−ａ］ピリミジン誘導体
WO2013039785A2 (en) Heterocyclic inhibitors of histamine receptors for the treatment of disease
HK1181038B (en) Tetrazolo[1,5-a]pyrazine compounds as inhibitors of histamine receptors